November 21, 2024
Find the most appropriate screen to accelerate your drug development: discover how our in vitro cell line screening, OmniScreen™, provides key information on the cytotoxicity and chemotherapeutic potential of your agent, and how our in vivo screening platform, MuScreen™, is the only high throughput in vivo screen available to evaluate your immune-modulating agent across panels of well-characterized syngeneic and tumor homograft models.
Use cost-effective, rapid, and large-scale cancer cell line screening to advance your lead compound to validated candidate.
Leverage OrganoidXplore's pioneering platform for large-scale organoid panel drug screening, achieving research at triple the speed with our assay-ready technology.
Fast-track your in vivo immunotherapy development with large-scale syngeneic and tumor homograft screening.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-09-23
2021-10-26